Technical Analysis for ALLO - Allogene Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 26.93 4.42% 1.14
ALLO closed up 4.42 percent on Tuesday, April 23, 2019, on 70 percent of normal volume.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical ALLO trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish 4.42%
Oversold Stochastic Weakness 4.42%
Oversold Stochastic Weakness 3.78%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.36%
Outside Day Range Expansion 5.36%
Oversold Stochastic Weakness 5.36%
Narrow Range Bar Range Contraction 2.51%

Older signals for ALLO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Biotechnology Cancer Life Sciences Stem Cells Cell Biology Therapy Cell Therapy Therapies For Cancer Kite Pharma Adoptive Cell Transfer
Is ALLO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Apr 15 Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
Apr 6 Stocks To Watch: Disney+ And Bank Majors Step Out
Apr 3 Allogene Therapeutics Announces April 2019 Investor Conference Schedule 
Apr 1 Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
Mar 29 Benzinga's Top Upgrades, Downgrades For March 29, 2019
Mar 14 All You Need To Know About Allogene Therapeutics, Inc.’s (NASDAQ:ALLO) Financial Health
Mar 14 Benzinga's Top Upgrades, Downgrades For March 14, 2019
Mar 9 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2018 Results - Earnings Call Transcript
Mar 8 Allogene Therapeutics misses by $0.05
Mar 8 Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
See more ALLO news...
Indicators
Indicator Value
52 Week High 35.55
52 Week Low 21.67
Average Volume 446,103
200-Day Moving Average 0.0
50-Day Moving Average 28.4326
20-Day Moving Average 26.9575
10-Day Moving Average 26.332
Average True Range 1.0771
ADX 16.79
+DI 18.8944
-DI 21.8033
Chandelier Exit (Long, 3 ATRs ) 26.3487
Chandelier Exit (Short, 3 ATRs ) 27.8313
Upper Bollinger Band 28.9546
Lower Bollinger Band 24.9604
Percent B (%b) 0.49
BandWidth 14.816656
MACD Line -0.525
MACD Signal Line -0.5308
MACD Histogram 0.0059
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.14
Resistance 3 (R3) 28.92 27.96 28.77
Resistance 2 (R2) 27.96 27.40 28.07 28.65
Resistance 1 (R1) 27.44 27.05 27.70 27.67 28.53
Pivot Point 26.49 26.49 26.61 26.60 26.49
Support 1 (S1) 25.97 25.92 26.23 26.19 25.33
Support 2 (S2) 25.01 25.58 25.12 25.21
Support 3 (S3) 24.50 25.01 25.09
Support 4 (S4) 24.72